Loading...
Market
How will Precision BioSciences' stock react to PBGENE-HBV trial results?
2
Resolution / Starting Odds
Stock price increases by more than 10% • 25%
Stock price increases by less than 10% • 25%
Stock price remains stable • 25%
Stock price decreases • 25%
Stock market data for Precision BioSciences
Story
Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B
Oct 24, 2024, 12:51 PM
Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.
View original story
Similar markets
Stock rises by more than 10% • 25%
Stock rises by 0-10% • 25%
Stock falls by 0-10% • 25%
Stock falls by more than 10% • 25%
Increase by more than 10% • 25%
Increase by 0% to 10% • 25%
No significant change • 25%
Decrease • 25%
Increase by over 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by over 10% • 25%
Increase by more than 20% • 25%
Increase by 10% to 20% • 25%
Change less than 10% • 25%
Decrease • 25%
Increase over 20% • 25%
Increase 0-20% • 25%
No change • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increases by more than 10% • 25%
Increases by 0-10% • 25%
Decreases by 0-10% • 25%
Decreases by more than 10% • 25%
Increase > 20% • 25%
Increase 10-20% • 25%
Increase < 10% • 25%
Decrease • 25%
Up by more than 50% • 25%
Up by 0% to 50% • 25%
Down by 0% to 50% • 25%
Down by more than 50% • 25%
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
Increases by more than 10% • 25%
Decreases by more than 10% • 25%
Changes by less than 10% • 25%
No significant change • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%